ZURICH (Reuters) – Swiss biotechnology company Molecular Partners is getting a payment from the Swiss government in the “high single digit millions” of Swiss francs to reserve doses of an early-stage drug candidate it hopes will work against COVID-19.
“The initial supply agreement secures the right to purchase 200,000 doses, with the potential to purchase up to an additional 3 million doses,” said Molecular Partners on Tuesday. The company hopes to start initial clinical studies later this year on the experimental drug, called MP0420.
(Reporting by John Miller; Editing by Jacqueline Wong)
